How to appeal a Premera Blue Cross inflammatory bowel disease (crohn's + uc) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Premera Blue Cross-specific note: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.

What Premera Blue Cross's policy requires for inflammatory bowel disease (crohn's + uc)

Cited policy: BCBS Rinvoq (Upadacitinib) for UC + Crohn's PA

Moderate-severe UC (FDA Mar 2022) or CD (FDA May 2023). Failure or intolerance of >=1 anti-TNF OR contraindication. Induction 45 mg PO daily x 8 wk (UC) or 12 wk (CD), then 15 mg or 30 mg maintenance. TB / HBV / HCV / lipids / CBC screening required. Boxed-warning risk discussion documented.

How Premera Blue Cross denies inflammatory bowel disease (crohn's + uc) — and how to counter it

Where Premera Blue Cross pushes back: 1) JAK boxed warning — must fail 2 biologics first; 2) Patient >50 — denied per ORAL-Surveillance; 3) Must try Stelara/Entyvio before JAK.

Counter-arguments that hold up: Rinvoq UC FDA Mar 16, 2022 (U-ACHIEVE + U-ACCOMPLISH Danese Lancet 2022); Rinvoq CD FDA May 18, 2023 (U-EXCEED + U-EXCEL Loftus NEJM 2023). ORAL-Surveillance (Ytterberg NEJM 2022;386:316) was a POST-MARKETING RA cohort >=50 with >=1 CV risk factor — NOT IBD; class boxed warning is patient-specific. AGA UC 2020 + CD 2020 list JAK as parallel option after TNFi failure (or alternative if TNFi contraindicated). Document patient-specific CV / malignancy / VTE risk vs benefit.

What Premera Blue Cross typically denies for inflammatory bowel disease (crohn's + uc)

Across Premera Blue Cross's commercial and Medicare books, denials cluster around a small number of patterns. For inflammatory bowel disease (crohn's + uc), expect:

• WA-specific mental health parity violations
• Step therapy via Express Scripts
• Out-of-network reductions
• Specialty drug prior auth

Treatments most often denied in this category

These are the inflammatory bowel disease (crohn's + uc) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira (adalimumab)
• Remicade (infliximab)
• Cimzia (CD only)
• Simponi (UC only)
• Stelara (ustekinumab)
• Skyrizi (risankizumab)

How to submit the appeal to Premera Blue Cross

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Premera Blue Cross cited in the denial.
3. File the appeal through Premera Blue Cross's portal (members: https://www.premera.com ; providers: https://www.premera.com/wa/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In WA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Premera Blue Cross's prior-authorization criteria by drug: Premera Blue Cross PA criteria on ApprovalHelp.